Company Filing History:
Years Active: 1995-1998
Title: Innovations in HIV-1 Treatment by Inventor Kang Lin
Introduction
Kang Lin is a notable inventor based in New York, NY (US), recognized for his contributions to the field of HIV-1 treatment. With a total of two patents, he has made significant strides in developing synthetic polypeptides aimed at inhibiting HIV-1 infections. His work is crucial in the ongoing battle against this virus.
Latest Patents
Kang Lin's latest patents focus on synthetic polypeptides as inhibitors of HIV-1. The first patent describes a synthetic HIV-1-based polypeptide that provides methods for treating HIV-1 infections. This polypeptide has an amino acid sequence that corresponds to a specific region of the HIV-1.sub.IIIB virus. It can be administered in effective amounts to prevent and treat HIV-1 infections. The polypeptide is designed to inhibit the replication of the HIV-1 virus, as well as HIV-1-mediated cytopathogenesis and cell fusion, while maintaining acceptable levels of cytotoxicity. The second patent also addresses synthetic polypeptides for topically inhibiting HIV-1 infectivity or replication, further emphasizing the versatility and potential of his inventions.
Career Highlights
Kang Lin is affiliated with the New York Blood Center, Inc., where he continues to innovate in the field of virology. His work has garnered attention for its potential impact on public health and the treatment of HIV-1.
Collaborations
Kang Lin has collaborated with notable colleagues, including Shibo Jiang and A Robert Neurath. These partnerships have likely contributed to the advancement of his research and the development of his patents.
Conclusion
Kang Lin's innovative work in developing synthetic polypeptides as inhibitors of HIV-1 showcases his commitment to addressing critical health challenges. His contributions are paving the way for new treatment options in the fight against HIV-1 infections.